Diligence memo · auto-generated · as of July 2, 2026
Vesicle Therapeutics Inc.
Vesicle Therapeutics Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Vesicle Therapeutics Inc. operates in Biotechnology, based in NIWOT.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vesicle Therapeutics Inc. has raised $800K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $800K on 2022-04-05.
Most recent recorded round closed around 2022-04-05.
Valuation (modeled)modeled
Provath models Vesicle Therapeutics Inc. at approximately $15M (range $427K–$99M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 4.60× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.2 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 15% of Biotechnology peers (4293 compared).
Modeled value ranks above 24% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., TAUC3 Biologics Ltd, UCHU Biosensors, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.